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A B S T R AC T
Nonsteroidal anti-inflammatory drugs (NSAIDs) are a 
major cause of hypersensitivity reactions. Several distinct 
clinical syndromes are described regarding NSAID 
hypersensitivity. Such a reaction is generally caused 
by a non-immunological mechanism. In susceptible 
patients, COX-1 inhibition leads to an imbalance in lipid 
mediators such as leukotrienes and prostaglandins. 
It is essential to distinguish multiple nonspecific NSAID 
hypersensitivity from single NSAID hypersensitivity, 
since the management of these respective syndromes is 
essentially different. This review provides an overview on 
all the aspects of NSAID hypersensitivity reactions, from 
pathophysiology to clinical symptoms, leading practical 
recommendations. 
K E Y WOR DS
Acetylsalicylic acid, asthma, drug allergy, hypersensitivity, 
nonsteroidal anti-inflammatory drugs
I N T RODUC T I ON
Nonsteroidal anti-inf lammatory drugs (NSAIDs) 
are among the most used drugs worldwide. It is 
therefore not surprising that they are a major cause of 
hypersensitivity reactions, accounting for up to 48.7% of 
drug-related ‘allergic’ reactions.1-3 Various mechanisms are 
distinguished through which NSAIDs can cause hypersen-
sitivity reactions in humans, all leading to quite similar 
symptoms making it difficult to determine the cause in a 
specific patient. Adding to the confusion of clinicians is the 
different terminology and many abbreviations that are used 
in the medical literature. This review provides an overview 
of the pathophysiology and clinical aspects of NSAID 
hypersensitivity and ends with practical recommendations. 
C A SE  1
A 35-year-old male presents to his general practitioner 
because of alleged reactions to various NSAIDs. He recalls 
that he had his first reaction about ten years ago consisting 
of swelling and redness of the eyes shortly after ingestion 
of ibuprofen. One year ago, swelling of the lips occurred 
one hour after ingestion of naproxen. Recently, similar 
symptoms developed three hours after the ingestion of 
1000 mg of acetaminophen. His medical history reveals 
childhood asthma, and mild allergic rhinoconjunctivitis 
in the spring. He does not take any daily medications. 
He asks which analgesic he can safely use after an 
upcoming dentist procedure.
What is the correct diagnosis and what advice should the 
patient receive?
C A SE  2
A 56-year-old male is referred to the Allergy outpatient 
clinic because of a recent reaction to diclofenac. The patient 
endured an accident when cycling and had several bruised 
ribs for which diclofenac 50 mg, three times daily, 
was prescribed. On the third day, he developed rapidly 
progressive urticaria, abdominal cramps, and started 
perspiring heavily, 30 minutes after ingestion of diclofenac. 
He did not notice any respiratory symptoms. At the 
Emergency Department, hypotension was found. He has 
used ibuprofen, diclofenac and acetaminophen in the past 
without any reactions. 
What is the correct diagnosis and what test could aid in this 
diagnosis?
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C A SE  3 
A 30-year-old woman presents with dyspnoea after taking 
ibuprofen for a sprained ankle. One hour after the first 
dose, nasal congestion and dyspnoea occurred. When she 
presented at the Emergency Department, severe wheezing 
was noted. The patient did not have a rash or angioedema. 
She was treated with salbutamol inhalation, intravenous 
corticosteroids and xylometazoline nose spray. The medical 
history of the patient revealed constitutional eczema and 
atopic asthma for which she used high doses of inhaled 
corticosteroids with a long-acting beta agonist.
What is the correct diagnosis and which analgesics are safe for 
this patient?
PAT HOPH Y S I O L O G Y  O F  N S A I D 
H Y P E R S E N S I T I V I T Y
NSAIDs are a large group of drugs that block the enzyme 
cyclooxygenase (COX), thereby inhibiting the production 
of prostaglandins from arachidonic acid.4 Figure 1 provides 
an overview of the most used NSAIDs. Arachidonic acid 
is metabolised by two pathways: the COX pathway, which 
induces synthesis of prostaglandins, and the lipoxygenase 
pathway, which induces synthesis of cysteinyl-leukotrienes 
and thromboxane. There are at least two isoforms of 
COX. COX-1 is constitutively expressed by specific cells 
such as thrombocytes and endothelial cells. COX-2 is 
inducible by pro-inflammatory mediators in a wide variety 
of cells.4 In susceptible patients, COX-1 blockade leads 
to a relative increase in cysteine-leukotriene synthesis 
causing inflammation of the respiratory tract.5,6 This is 
due to a constitutively disrupted balance between pro- 
and anti-inflammatory prostaglandins and leukotrienes 
in patients with multiple NSAID hypersensitivity 
(figure 2). Here, pro-inflammatory cysteinyl-leukotrienes 
are continually upregulated and the anti-inflammatory 
prostaglandin E
2
 is downregulated.7-9 The latter 
appears to be a consequence of the downregulation of 
COX-2.6,10 When COX-1 is then blocked by an NSAID, 
the prostaglandin production is further decreased. This 
amplifies the pre-existent imbalance in favour of the 
cysteinyl-leukotrienes, which can induce bronchospasm, 
vascular leakage, eosinophilic inflammation and mast cell 
activation.9,11,12 Although cysteinyl-leukotrienes appear to 
play a main role in the mechanism for NSAID-exacerbated 
respiratory disease (NERD) and NSAID-exacerbated 
cutaneous disease (NECD), there is evidence for additional 
Figure 1. Visual summary of the COX-1 and/or 
COX-2 inhibiting properties of the most used NSAIDs 
in the Netherlands. Ketorolac and indomethacin are 
strong COX-1 inhibitors.49,50 Rofecoxib and etoricoxib 
are the most selective COX-2 inhibitors
Figure 2. Schematic figure showing the pathophysiology 


















The enzymes cyclooxygenase (COX) and 5-lipoxygenase (5-LO) 
regulate the production of prostaglandins and thromboxane, and 
leukotrienes, respectively, from arachidonic acid. Under physiological 
circumstances, pro- and anti-inflammatory eicosanoids are 
balanced to maintain homeostasis (panel A). In NERD, the levels 
of pro-inflammatory cysteinyl-leukotrienes (cys-LT) are elevated. 





are decreased due to downregulation of COX-2 (panel B). The use of 
NSAIDs leads to further imbalance by blocking COX-1, and often also 
COX-2 (panel C), thereby causing clinical symptoms due to a relative 
overload of pro-inflammatory cysteinyl-leukotrienes.5,6,8
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 cells, granulocytes, and 
thrombocytes.11,13,14 
D I F F E R E N T  F OR MS  O F  N S A I D 
H Y P E R S E N S I T I V I T Y
There are four clinical phenotypes of immediate-type 
NSAID hypersensitivity: NERD, NECD, NSAID induced 
urticaria/angioedema (NIUA), or single NSAID induced 
urticaria/angioedema/anaphylaxis (SNIUAA). The last 
mentioned is a specific, probably IgE-mediated, allergy. 
The other phenotypes do not have an immunological 
pathophysiology, but are caused by inhibiting of COX-1 
resulting in an imbalance in eicosanoid mediators, as 
outlined further. The terms pseudo-allergy and intolerance 
were commonly used in the past to indicate this type of 
reaction but are outdated.15 Next to these immediate-type 
hypersensitivity syndromes, a delayed-type hypersensitivity 
syndrome is termed ‘single NSAID-induced delayed type 
reaction’ (SNIDR). 
NON - I MMUNOLOG I C A L LY  M ED I A T E D 
( C RO S S - R E AC T I V E )  N S A I D  I N DUC ED 
H Y P E R S E N S I T I V I T Y  R E AC T I ONS
NSAID-exacerbated respiratory disease (NERD)
This phenotype is also known as aspirin-exacerbated 
respiratory disease or the ‘acetylsalicylic acid (ASA) triad’.15 
Around 7-14% of adult asthma patients have NERD.16,17 
Contrary to allergic asthma, NERD commonly starts in 
early adulthood.18 It is characterised by refractory polyposis 
nasi, sinusitis, modest to severe asthma, and hypersen-
sitivity reactions to various types of NSAID with COX-1 
inhibiting properties. The asthma is often severe and 
corticosteroid-dependent. However, not all patients have 
the full triad, as rhinosinusitis typically precedes asthma 
by 1-3 years. Consequently, not all patients have clinically 
overt asthma: they may experience their first ‘asthma 
exacerbation’ only after NSAID ingestion.18 Many patients 
have anosmia and often need sinus surgery.14 Ingestion 
of an NSAID (mainly, but not exclusively, those with 
strong COX-1 inhibition) will lead to an exacerbation of 
asthma and/or rhinitis and sometimes also angioedema. 
The reaction can be delayed for several hours. The mean 
provoking dose was around 80 mg in different studies; 
however, reactions are described at doses as low as 
10 mg.16,19 
NSAID-exacerbated cutaneous disease (NECD)
NECD is actually the cutaneous variant of NERD. Patients 
with NECD suffer from chronic spontaneous urticaria 
(CSU) and/or angioedema and experience worsening 
of these symptoms after the ingestion of an NSAID.20 
Although most reactions include urticaria, isolated 
angioedema is a possible manifestation of NECD.21 The 
incidence of NECD is estimated to be 12-30% in CSU 
patients.22 NECD patients did not react to selective COX-2 
inhibitors in several studies.23,24 
Since CSU is often a self-limiting disease within months 
to years, NECD can potentially recover with the resolution 
of CSU. However, NECD patients seem to have a distinct 
phenotype compared with NSAID-tolerant CSU patients: 
the latter have a shorter duration of CSU and less often 
have angioedema when compared with NECD patients.25 
To our knowledge, there are no comprehensive data on the 
resolution of NECD.
NSAID-induced urticaria/angioedema (NIUA)
Patients with NIUA do not have spontaneous urticaria and/
or angioedema, but only develop them after the ingestion 
of an NSAID. As with NERD and NECD, NIUA is a 
multiple NSAID hypersensitivity syndrome and there is 
cross-reactivity between chemically nonrelated NSAIDs.22 
Since patients often start to avoid NSAIDs after their first 
reaction, this cross-reactivity might not always be clear. 
Patients can report isolated urticaria, angioedema or a 
combination of both. Approximately 60% of all patients 
with NIUA have concomitant atopic disease, although 
a hypothesis for a pathophysiological mechanism for 
this association is lacking.22,26 The pathophysiological 
basis for NIUA appears similar to that of NERD and 
NECD, as several polymorphisms were detected in genes 
related to arachidonic acid metabolism.27,28 Spanish 
studies reveal that 62% of NIUA patients spontaneously 
develop tolerance to NSAIDs after five years. Risk factors 
for persistent NSAID hypersensitivity are atopy and 
isolated angioedema.29,30 Conversely, 33% of patients with 
NIUA developed chronic spontaneous urticaria during 
follow-up.31 These patients thus actually had NECD with 
delayed presentation of the spontaneous urticaria.
I MMUNOLOG I C A L LY  M ED I A T E D 
S P E C I F I C  N S A I D  H Y P E R S E N S I T I V I T Y 
R E AC T I ONS
Single NSAID induced urticaria/angioedema or 
anaphylaxis (SNIUAA)
SNIUAA is biologically and phenotypically distinct from 
the other NSAID hypersensitivity syndromes. Patients 
only react to one NSAID or multiple NSAIDs with 
similar chemical structures. It usually consists of a 
rapid, systemic anaphylactic reaction, resembling type-I 
hypersensitivity.3,32 Reactions are generally more severe 
than in the previous syndromes. SNIUAA can also present 
with isolated urticaria and/or angioedema, although 
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isolated angioedema is unlikely. The fact that patients 
with SNIUAA can tolerate other NSAIDs than the culprit 
drug suggests a sensitisation for a certain epitope in the 
NSAID in question. Until now, sensitisation tests such 
as specific IgE measurement and skin testing were often 
negative.3,33 Possibly, there is only a small time window in 
which specific IgE is detectable, or the reaction might not 
be IgE mediated at all.34 
Single NSAID induced delayed reactions (SNIDR) 
SNIDR is a highly heterogeneous group of clinical entities 
usually occurring within 24-48 hours after the ingestion 
of an NSAID. The entities range from mild reactions such 
as a maculopapular rash, to severe allergic syndromes 
such as acute generalised exanthematous pustulosis or 
toxic epidermal necrolysis.35 The putative mechanism is 
T-cell mediated. Due the fact that these reactions can be 
life-threatening, randomised studies are lacking and the 
possibility of cross-reactivity has not been elucidated. 
Because the scope of this review is immediate-type NSAID 
hypersensitivity reactions, SNIDR will not be discussed 
further.
D I AGNOS T I C  S T R AT EG I E S
All patients with a reaction to an NSAID should be advised 
to avoid all NSAIDs until more certainty is obtained 
about cross-reactivity. As outlined previously, SNIUAA 
typically presents with acute, systemic reactions to the 
culprit drug, and tolerance to other NSAIDs. However, the 
clinical symptoms of the above-described hypersensitivity 
syndromes can overlap, since SNIUAA can also present 
with isolated urticaria, and patient histories are not always 
reliable.36 Furthermore, most patients avoid NSAIDs 
after their first reaction, and information on clinical 
cross-reactivity is lacking. Comorbidities can aid in the 
diagnosis: patients with a history of chronic spontaneous 
urticaria or a combination of asthma, rhinitis, and nasal 
polyps are likely to be multiple reactors (table 1). 
Common allergologic diagnostic procedures are not 
suitable for NSAID hypersensitivity. The European 
Academy of Allergy and Clinical Immunology (EAACI) 
position paper does not recommend skin tests as part 
of the diagnostic work up.37 Specific IgE and basophil 
activation tests are not reliable in this context.3,15,38 There is 
also no association between NSAID hypersensitivity and 
serum tryptase levels.39 Since multiple NSAID reactors 
have raised levels of prostaglandin D
2
 and leukotriene E
4
, 
measurement of these levels might identify persons at risk 
for NSAID hypersensitivity.7,40,41 However, these cannot be 
used for a final diagnosis. 
A provocation challenge remains the gold standard.22 The 
goal of such a drug challenge can be twofold; it can either 
establish the diagnosis or identify a safe alternative NSAID. 
Since ASA is among the strongest COX-1 inhibitors 
(figure 1), this is often used to test for general NSAID 
hypersensitivity, depending on the patient history and 
anticipated risk of the provocation challenge itself.42 See 
figure 3 for a decision model. Contraindications for a 
provocation challenge are: severe asthma (FEV1 < 70% 
of predicted, use of short-acting beta-agonist ≥ 3 
times a week, nightly dyspnoea), active spontaneous 
urticaria/angioedema in the last two weeks, pregnancy, 
active infection, and a recent vaccination (≤ 1 week). 
Relative contraindications are the use of beta-blockers 
or ACE-inhibitors.22,43 In order to avoid false-negative 
results, histamine and leukotriene antagonists need to 
Table 1. Summary of different NSAID hypersensitivity syndromes
Timing of reaction ≤ 24 hours ≤ 2 hours
Reaction to multiple NSAIDs? Yes Yes No
Type of reaction Urticaria and/or angioedema Bronchospasm, nasal 
congestion, rhinorrhoea
Anaphylaxis*
Underlying disease None† Chronic spontaneous 
urticaria and/or angioedema
Asthma with polyposis nasi, 
and/or chronic recurring 
sinusitis
None
Diagnosis NIUA NECD NERD SNIUAA
Risk of reaction to COX-2 inhibitor23,24 6%-25%‡ 17.4% 0-8.7% 0%
Risk of reaction to acetaminophen24 12.5% 43.9% 33.3% 0%
NIUA = NSAID-induced urticaria/angioedema ; NECD = NSAID exacerbated cutaneous disease ; NERD = NSAID exacerbated respiratory disease ; 
SNIUAA = single NSAID induced urticaria/angioedema or anaphylaxis.
*Only urticaria also possible; †Approximately 60% of patients with NIUA have atopic disease; ‡Risk 6% if acetaminophen tolerant, and 25% for patients 
who also have acetaminophen hypersensitivity.
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be discontinued at least three days before the challenge.44 
Inhalation medication for asthma should be continued for 
safety reasons. The use of a standardised scoring system 
and a double-blind, placebo-controlled format can increase 
the reliability of a drug challenge.45
If a patient has a history of multiple NSAID reactions 
and/or spontaneous urticaria, angioedema or chronic 
respiratory disease (asthma, rhinitis etc.), the likelihood of 
multiple NSAID hypersensitivity is very high. A challenge 
with ASA can in such cases cause cumbersome symptoms 
or even life-threatening asthma exacerbations. Therefore, 
it is preferred to directly perform a challenge with an 
alternative, for instance a specific COX-2 inhibitor, in 
these patients. When SNIUAA is assumed, it can be 
unnecessarily hazardous to challenge the patient with the 
culprit drug. It is then preferred to perform a challenge 
with ASA to exclude a multiple NSAID hypersensitivity 
syndrome. If ASA is tolerated well, the patient is advised 
to only avoid the culprit NSAID, and other classes will be 
safe. The patients that present with isolated urticaria after 
NSAID ingestion without any relevant history are the most 
difficult to categorise. With the aforementioned strategy, 
they would first undergo ASA challenge to distinguish 
between NIUA or SNIUAA. Often, the history is not clear 
at all, and the first goal is to establish any type of causality 
between the NSAID ingestion and the reaction. Depending 
on the severity of the previous reaction, a challenge with 
the culprit drug can then be performed first. If that 
Figure 3. Flowchart of the decision process regarding the management of a patient who has one or more reported 
immediate-type reactions to NSAIDs which has raised the suspicion of NSAID hypersensitivity
Suggestive history 
Suggestive history







-(High-dose beta blocker use)
Patient with an alleged 
reaction to NSAID 
History of CSU/respiratory disease 
and/or 
Reaction to >1 NSAIDs 
Reaction to 1 NSAID 
without 
History of CSU/respiratory disease 
Likely multiple NSAID 
hypersensitivity syndrome: 
NECD, NERD, NIUA (table 1) 
Perform challenge 
with acetaminophen 
and/or celecoxib to 














*if ASA was the culprit drug, perform challenge
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challenge is negative, any type of NSAID hypersensitivity 
can be excluded. If the challenge to the culprit drug is 
positive, the Allergist can decide to challenge with ASA 
to further distinguish between single or multiple NSAID 
hypersensitivity. Of note, drug challenges always pose a 
certain risk, depending on the phenotype of the patient, as 
outlined previously. Therefore, these challenges should be 
performed by experienced Allergists with the appropriate 
resources and access to emergency medical care.
A F T E R  T H E  D I AGNO S I S :  A L T E R NAT I V E 
A NA L G E S I C S  A N D  D E S E N S I T I S A T I ON
Depending on the diagnosis and outcome of the ASA 
challenge, the patient can be advised to avoid only the 
culprit or all NSAIDs. Then, there might be a need to 
investigate the safety of alternative analgesics. The risk 
of hypersensitivity reactions to acetaminophen varies 
between the different subtypes of NSAID hypersensitivity. 
Numbers between 9.6% and 43.9% have been reported.24,46 
It is advised to perform a challenge that ends with a 
sufficiently high dose of acetaminophen (1000 mg) in all 
patients with multiple NSAID hypersensitivity. Selective 
COX-2 inhibitors are often a safe alternative, especially 
in patients who can tolerate acetaminophen. In the latter, 
only 6% of patients with NIUA reacted to a selective COX-2 
inhibitor, and in NERD, the risk was actually zero.23,47 
It must be noted that the patients in these studies had 
mild-to-moderate asthma, and the risk of reaction to a 
COX-2 inhibitor in patients with severe asthma might 
be higher. Since there are no similar studies among 
patients with NERD and severe asthma, it is advisable 
to treat the asthma appropriately before performing any 
drug challenge. Patients with NECD have the highest 
risk of cross-reactivity with both acetaminophen and 
selective COX-2 inhibitors (table 2). Thus, an additional 
challenge with a specific COX-2 inhibitor should be the 
next step in the evaluation of patients with multiple NSAID 
hypersensitivity, especially when they have also reacted to 
acetaminophen. Re-evaluation after five to six years can 
be considered in patients with NECD or NIUA, because a 
substantial number develop tolerance to all NSAIDs.29,30 
Patients with cardiovascular disease are often 
recommended to use a daily low dose of up to 100 mg ASA, 
which can cause a problem for multiple NSAID reactors. 
Fortunately, low doses are often tolerated. If patients 
do react to these low doses, ASA desensitisation can 
be attempted. Desensitisation is a procedure aimed at 
inducing a pharmacological or immunological tolerance 
to the drug. There is no international standard for this 
procedure and many different desensitisation schedules 
are described in the literature. Of course, it is essential that 
the patient’s asthma is well controlled. Table 2 provides two 
possible schedules for desensitisation.48 Daily use of ASA 
after the desensitisation is necessary to maintain tolerance. 
CONC LUS I ONS
There are several different NSAID hypersensitivity 
syndromes. The distinction between multiple and single 
NSAID reactivity is pivotal and can largely be made based 
on the patient’s history. Provocation challenges are the gold 
standard to confirm NSAID hypersensitivity, or to find safe 
alternatives. ASA desensitisation is a safe and effective 
method for patients who have a strict indication. 
A NSW ER S
Case 1
The reactions to different NSAIDs and the time lag 
between ingestion and reaction are suggestive of a multiple 
NSAID hypersensitivity syndrome. Furthermore, the 
absence of current asthma, sinusitis, rhinitis, nasal 
polyps or spontaneous urticaria/angioedema argues 
Table 2. Examples of acetylsalicylic acid 
desensitisation schedules


















17:00 End of desensitisation
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for a diagnosis of NIUA. Up to 25% of patients with 
NIUA also have hypersensitivity reactions to high-dose 
acetaminophen (i.e., ≥ 1000 mg) thus it is not surprising 
that the patient reported reactions to acetaminophen too. 
A selective COX-2 inhibitor, such as celecoxib, is tolerated 
in most patients with NIUA. To find out, it was advised 
to perform an open provocation challenge with celecoxib. 
Case 2
This patient had generalised urticaria with hypotension, 
fulfilling the definition of severe anaphylaxis, rapidly after 
ingestion of diclofenac. This clinical pattern, combined 
with the fact that he did not have respiratory disease 
or CSU, is suggestive of a specific diclofenac allergy 
(SNIUAA). Because this case is clear-cut, a challenge with 
diclofenac is not needed to establish the diagnosis. Even in 
case of a doubtful history, a challenge test with diclofenac 
should be avoided because of a possible severe reaction 
during challenge. In this patient a challenge test with 
ASA is indicated to find out if alternative NSAIDs can be 
tolerated. 
Case 3
It is highly likely that this patient has NERD, because 
of the combination of respiratory distress with nasal 
congestion and the medical history of moderately severe 
asthma. She should be advised to avoid all classic NSAIDs. 
A challenge with COX-2 would be useful to find out 
whether this is a safe alternative for her. The risk of 
hypersensitivity reactions to acetaminophen is negligible 
for patients with NERD.
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